CPHI Webinar Series

Co-processing: A Multifaceted Approach for Enhancing Density & Powder Flow

19th September, 2023
4pm CET / 10am EST
What will this webinar address?

Discover the Power of Co-processing: Unleashing the Potential of Pharmaceutical Manufacturing. Our multifaceted co-processing technology is a game-changer, boosting density, optimizing powder flow, ensuring content uniformity, and enhancing solubility-dissolution. But that's not all – it also goes above and beyond, safeguarding your workforce from potent Active Pharmaceutical Ingredients (APIs). Embrace innovation and efficiency with our cutting-edge co-processing solutions and elevate your pharmaceutical production to new heights. Experience the future of manufacturing!

  • Understand the potential of co-processing technology - what are the key benefits over existing solutions?
  • Discover how the industry is embracing co-processing technology
  • Learn some of the common techniques on the co-processing technology platform
  • See examples of how co-processing can improve powder flow and density, and improve formulation rigidity
San Kiang
Chief Technology Officer at Porton Pharmatech Co., Ltd.

San Kiang is the Chief Technology Officer Drug Product at J-Star Research/Porton. He deploys particle engineering and co-processing techniques to resolve API and formulation issues especially those related to powder flow and dosage form dissolution rates. As a Research Professor at Rutgers University, he worked on research projects in the Engineering Research Center for Structured Organic Particles and the Chemical Engineering Department. Research focus is on continuous manufacturing (CM) and particle engineering, more specifically how the material properties of API can be engineered and how these properties affect CM equipment train and drug product performance.

San Kiang has 35 years of pharmaceutical development and technology transfer experience in Bristol-Myers Squibb covering both Active Pharmaceutical Ingredient (API) and Drug Product (DP) areas. PhD chemical engineer with experience in directing multi-disciplinary teams in pharmaceutical, chemical, and biochemical development and manufacture. He directed and/or participated in 12 NDA projects that were eventually commercialized and successfully participated in one of the first NDA filings using QBD paradigm. In this filing, he led the use of risk assessment and process modeling with emphasis on fundamental mechanistic understanding for drug development. Well recognized expert in crystallization, particle engineering, reaction engineering, continuous processing (both DP and API), as well as the design of pharmaceutical composite materials through co-processing.

Kaushalendra Chaturvedi
Sr. Research Scientist, J-Star Research/Porton

Kaushalendra leads advancements in particle engineering and drug product risk assessment. He skillfully employs techniques like particle engineering, crystal engineering, and coprocessing to optimize the behavior and effectiveness of active pharmaceutical ingredients (API) and their respective formulations, placing an emphasis on enhancing powder flow, density, solubility, and dissolution rates.

This webinar is brought to you by

Co-processing: A Multifaceted Approach for Enhancing Density & Powder Flow
  • 19th September, 2023
  • 4pm CET / 10am EST
  • 60 minutes
  • Free
CPHI Newsletter

Get the latest from CPHI in your inbox every week.

You understand that your information will be used in accordance with our Privacy Policy, and that you may withdraw your permission to receive any of our communications at any time by clicking on the Unsubscribe link in the Newsletters or opting out on our unsubscribe page page.